Todd Gray

1.6k total citations
22 papers, 905 citations indexed

About

Todd Gray is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Todd Gray has authored 22 papers receiving a total of 905 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Rheumatology. Recurrent topics in Todd Gray's work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (4 papers) and Hepatitis C virus research (4 papers). Todd Gray is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (4 papers) and Hepatitis C virus research (4 papers). Todd Gray collaborates with scholars based in United States, Canada and South Korea. Todd Gray's co-authors include Erika Hamilton, Jorge Chaves, Virginia F. Borges, Alison Conlin, Marc C. Chamberlain, Alex Vo, Claus G. Roehrborn, Joanne Waldstreicher, Rashmi K. Murthy and Marc Gittelman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Hepatology.

In The Last Decade

Todd Gray

22 papers receiving 857 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Todd Gray United States 11 380 370 223 168 166 22 905
Tai‐Di Chen Taiwan 13 177 0.5× 167 0.5× 34 0.2× 90 0.5× 58 0.3× 36 580
Fumitake Hata Japan 22 157 0.4× 448 1.2× 25 0.1× 86 0.5× 95 0.6× 79 1.1k
Mark D. Hafermann United States 13 570 1.5× 207 0.6× 196 0.9× 155 0.9× 62 0.4× 32 1.4k
D B Siders United States 16 733 1.9× 186 0.5× 100 0.4× 297 1.8× 31 0.2× 26 980
Camilla Thellenberg‐Karlsson Sweden 18 933 2.5× 210 0.6× 36 0.2× 73 0.4× 50 0.3× 45 1.3k
Thomas Chromecki Austria 24 776 2.0× 523 1.4× 239 1.1× 30 0.2× 112 0.7× 57 1.8k
Hai X. Bui United States 17 188 0.5× 137 0.4× 22 0.1× 103 0.6× 127 0.8× 30 797
Keijiro Kiyoshima Japan 14 467 1.2× 151 0.4× 75 0.3× 106 0.6× 27 0.2× 41 850
A Premkumar United States 13 280 0.7× 134 0.4× 24 0.1× 92 0.5× 111 0.7× 26 869
Hiroaki Hazama Japan 12 84 0.2× 134 0.4× 13 0.1× 47 0.3× 345 2.1× 19 699

Countries citing papers authored by Todd Gray

Since Specialization
Citations

This map shows the geographic impact of Todd Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Gray more than expected).

Fields of papers citing papers by Todd Gray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Gray. The network helps show where Todd Gray may publish in the future.

Co-authorship network of co-authors of Todd Gray

This figure shows the co-authorship network connecting the top 25 collaborators of Todd Gray. A scholar is included among the top collaborators of Todd Gray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd Gray. Todd Gray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heerspink, Hiddo J.L., Alan G. Jardine, Donald E. Kohan, et al.. (2024). Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. Kidney International Reports. 10(1). 217–226. 6 indexed citations
2.
Heerspink, Hiddo J.L., Meg Jardine, Donald E. Kohan, et al.. (2024). Atrasentan in Patients with IgA Nephropathy. New England Journal of Medicine. 392(6). 544–554. 27 indexed citations
3.
Gartner, Elaina M., et al.. (2022). Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer. Cancer Chemotherapy and Pharmacology. 90(5). 399–408. 8 indexed citations
4.
Meric‐Bernstam, Funda, Diana L. Hanna, Anthony B. El-Khoueiry, et al.. (2021). Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.. Journal of Clinical Oncology. 39(3_suppl). 299–299. 51 indexed citations
5.
Meric‐Bernstam, Funda, Erika Hamilton, Muralidhar Beeram, et al.. (2021). Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.. Journal of Clinical Oncology. 39(3_suppl). 164–164. 34 indexed citations
6.
Oh, Do‐Youn, Erika Hamilton, Diana L. Hanna, et al.. (2019). Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. Annals of Oncology. 30. ix22–ix22. 9 indexed citations
7.
Meric‐Bernstam, Funda, Jorge Chaves, Do‐Youn Oh, et al.. (2019). Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer. Molecular Cancer Therapeutics. 18(12_Supplement). B001–B001. 3 indexed citations
8.
Murthy, Rashmi K., Virginia F. Borges, Alison Conlin, et al.. (2018). Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. The Lancet Oncology. 19(7). 880–888. 129 indexed citations
9.
Murthy, Rashmi K., Erika Hamilton, Cristiano Ferrario, et al.. (2018). Clinical benefit of tucatinib after isolated brain progression: A retrospective pooled analysis of tucatinib phase 1b studies in HER2+ breast cancer.. Journal of Clinical Oncology. 36(15_suppl). 1015–1015. 5 indexed citations
10.
Borges, Virginia F., Cristiano Ferrario, Nathalie Aucoin, et al.. (2018). Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer. JAMA Oncology. 4(9). 1214–1214. 117 indexed citations
11.
12.
Fredlund, Paul, Jan Hillson, Todd Gray, et al.. (2015). Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C. Journal of Interferon & Cytokine Research. 35(11). 841–843. 5 indexed citations
13.
Tutrone, Ronald, Chiledum Ahaghotu, Andrew J. Armstrong, et al.. (2015). Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience.. Journal of Clinical Oncology. 33(7_suppl). 272–272. 2 indexed citations
14.
Higano, Celestia S., Oliver Sartor, Nicholas J. Vogelzang, et al.. (2015). Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry.. Journal of Clinical Oncology. 33(15_suppl). e16027–e16027. 1 indexed citations
15.
16.
Muir, Andrew J., Mitchell L. Shiffman, Atif Zaman, et al.. (2010). Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection†. Hepatology. 52(3). 822–832. 192 indexed citations
17.
Greenhalgh, David G., Richard L. Gamelli, Jay N. Collins, et al.. (2009). Recombinant Thrombin: Safety and Immunogenicity in Burn Wound Excision and Grafting. Journal of Burn Care & Research. 30(3). 371–379. 23 indexed citations
18.
Shiffman, M., E. Läwitz, A. Zaman, et al.. (2009). 643 PEG-IFN-l: ANTIVIRAL ACTIVITY AND SAFETY PROFILE IN A 4-WEEK PHASE 1B STUDY IN RELAPSED GENOTYPE 1 HEPATITIS C INFECTION. Journal of Hepatology. 50. S237–S237. 17 indexed citations
19.
Roehrborn, Claus G., John D. McConnell, Brian Saltzman, et al.. (2002). Storage (Irritative) and Voiding (Obstructive) Symptoms as Predictors of Benign Prostatic Hyperplasia Progression and Related Outcomes. European Urology. 42(1). 1–6. 75 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tai‐Di Chen Breakdown of academic impact, for papers by Fumitake Hata Breakdown of academic impact, for papers by Mark D. Hafermann Breakdown of academic impact, for papers by D B Siders Breakdown of academic impact, for papers by Camilla Thellenberg‐Karlsson Breakdown of academic impact, for papers by Thomas Chromecki Breakdown of academic impact, for papers by Hai X. Bui Breakdown of academic impact, for papers by Keijiro Kiyoshima Breakdown of academic impact, for papers by A Premkumar Breakdown of academic impact, for papers by Hiroaki Hazama
Rankless by CCL
2026